Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03308045
Recruitment Status : Recruiting
First Posted : October 12, 2017
Last Update Posted : November 19, 2019
Sponsor:
Information provided by (Responsible Party):
Eyevensys ( EYEVENSYS S.A.S. )

Brief Summary:

Primary objective: safety and tolerability

Secondary objectives: additional indicators of long term safety and indicators of clinical activity

Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and biomarkers


Condition or disease Intervention/treatment Phase
Non-infectious Uveitis Biological: pEYS606 Phase 1 Phase 2

Detailed Description:

The maximum study duration per patient is 27 Weeks (including an up to 3 week screening period + 24 weeks follow-up after treatment).

The study is conducted in 2 parts. Part 1 is a dose escalation phase which will investigate three pEYS606 doses levels (lower, intermediate and higher dose) over 3 cohorts. Part 1 of the study has been completed. Part 2, the extension phase, which is now ongoing will confirm to safety of the maximum tolerated higher dose from Part 1 and allow a preliminary assessment of efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 29 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Clinical trial with a single arm
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis
Actual Study Start Date : April 4, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: pEYS606
Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
Biological: pEYS606
pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle




Primary Outcome Measures :
  1. Number of patients with treatment emergent adverse events [ Time Frame: 4 weeks ]
    Assessment of the safety and tolerability of EYS606


Secondary Outcome Measures :
  1. Change from baseline in ocular safety assessments [ Time Frame: 6 months ]
    Measured as change from baseline in adverse events, concomitant medications, intraocular pressure, electroretinogram, electrocardiogram, vital signs, physical exam and routine labs (blood and urinalysis)

  2. Improvement in best corrected visual acuity [ Time Frame: 6 months ]
    Measured as change from baseline eye in best corrected visual acuity using ETDRS scale

  3. Improvement in anterior chamber cell grade [ Time Frame: 6 months ]
    Measured as change from baseline in anterior cell grade according to the SUN scale

  4. Improvement in vitreous haze grade [ Time Frame: 6 months ]
    Measures as change from baseline in vitreous haze grade according to SUN scale

  5. Improvement in central retinal thickness [ Time Frame: 6 months ]
    Measures as change from baseline in central retinal thickness using ocular coherence tomography

  6. Change in corticosteroid dose [ Time Frame: 6 months ]
    Measures as change from baseline in prescribed dose of corticosteroids



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must be 18 years of age or older
  • Both female patients of childbearing potential and male patients able to father a child must agree to practice at least one effective method of birth control for six months following administration of study medication. Acceptable methods of birth control for this study include hormonal contraception (birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide or surgical sterilization (hysterectomy, tubal ligation or vasectomy). Patients with a hysterectomy or vasectomy (or have a partner with a hysterectomy or vasectomy) are exempt from using these methods of birth control.
  • Female patients of childbearing potential must not be pregnant or breast-feeding and must have a negative urine pregnancy test at baseline and throughout the study.
  • Voluntary written informed consent before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Patient has only one eligible eye with the following criteria:
  • non-infectious intermediate, posterior, or panuveitis,
  • media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus imaging,
  • macular atrophy, AND/OR degenerative macular edema, AND/OR advanced optic neuropathy, AND/OR macular scar,
  • Patients must maintain regiment of local and/or systemic corticosteroids between screening and baseline (if applicable).

Visual Criteria - Part 1

- BCVA of 0.1 (ETDRS of 35) or worse at screening in the treated eye, and BCVA of 0.32 or higher in the fellow eye.

Key Inclusion Criteria - Part 2

  • BCVA of ≤ 0.63 or 20/32 Snellen but ≥ 0.025 or 20/800 Snellen (equivalent to ≥ 5 and ≤ 77 ETDRS letters) in the treated eye
  • Patient must have a diagnosis of non-infectious uveitis of any anatomic subtype
  • Patient must have a history of chronic or recurrent uveitis requiring or having required treatment with corticosteroids (systemic, periocular or intraocular) and/or systemic immunosuppressive medication(s) in the 12 months prior to the screening visit
  • At the screening and baseline visits patient must have active uveitis as evidenced by at least one or more of the following in the study eye:

oActive retinal vasculitis (retinal vascular leakage) oVitreous haze grade ≥ 2+ oAnterior chamber cell grade ≥ 2+ oMacular edema

  • Patient receiving concomitant topical and/or systemic corticosteroids or allowed systemic immunosuppressive medications must have maintained the same treatment regimen (dosage/frequency) for at least 2 weeks prior to the baseline (V1) visit, (if applicable).
  • Willingness to receive local therapy to treat ocular inflammation in the fellow eye during the course of the study (if needed).

Exclusion Criteria:

  • Patient has or is suspected to have infectious uveitis or a uveitis masquerade syndrome.
  • Patient suspected to have tuberculosis, has had a positive test for tuberculosis in the past or has a positive γ-interferon tuberculosis test at the screening visit.
  • For a patient with a primary diagnosis of idiopathic intermediate uveitis exclusion of any signs of multiple sclerosis must be demonstrated by an MRI examination of the brain and orbits with gadolinium prior to the baseline visit.
  • Patient with macular edema as the only evidence of uveitis (e.g. absence of any vitreous haze or vasculitis) for which a non-uveitic cause of macular edema such as cataract extraction, age-related macular degeneration, diabetic retinopathy or retinal vein occlusion cannot be excluded.
  • Patient with media opacity in the study eye that precludes visualization of the fundus or that is likely to require cataract surgery during the course of the trial.
  • Patient with history of glaucoma filtering surgery (e.g. trabeculectomy or aqueous shunt implant) or who underwent eye surgery within 3 months in the treated eye.
  • Patient who has uncontrolled intraocular pressure of ≥ 25 mmHg in the study eye at the screening and baseline visits.
  • Patient with intraocular hypotension (<6 mmHg) that in the opinion of the Investigator would interfere with the administration of EYS606 or the evaluation of its safety or efficacy.
  • Patient with history of scleritis, scleral thinning, cicatrizing conjunctival diseases, severe ocular allergies or other severe ocular surface disease that could interfere with the administration of EYS606 or the evaluation of its safety or efficacy.
  • Patient has received Ozurdex® (dexamethasone implant) or other intraocular or periocular corticosteroids injections within 3 months prior to the baseline visit in the study eye
  • Patient has received a fluocinolone implant (Retisert®, Illuvien®, YutiqTM) within 12 months prior to the baseline visit in the study eye.
  • Patient has received treatment with a TNFα inhibitor intravitreally in the study eye within 2 months prior to the baseline visit.
  • Patient has received intravitreal anti-VEGF therapy such as Lucentis® (ranibizumab) or Avastin® (bevacizumab) or Eylea® (aflibercept) within 2 months prior to the baseline visit in the study eye.
  • Patient has received intravitreal methotrexate within 2 months prior to the baseline visit in the study eye.
  • Patient with a history of allergic reaction or intolerance to any routinely used ophthalmic medicines (e.g. fluorescein dye, topical dilating agents or local anesthetics) that will be prescribed during the course of the study.
  • Patient with active or uncontrolled underlying systemic autoimmune or inflammatory disease requiring or likely to require an increase in systemic immunosuppressive medications or treatment with a biologic agent during the course of the study.
  • Patient has received treatment with an alkylating agent (cyclophosphamide or chlorambucil) for the management of uveitis or an associated underlying disease.
  • Patient has received treatment with a systemic biologic therapy (e.g. anti-TNFα, anti-IL-1, anti-IL-6, anti-IL-17, interferon) within 1 month prior to the baseline visit.
  • Patient has received treatment with Rituximab within 6 months of the baseline visit.
  • Patient with a history of or current evidence of any unstable medical condition (such as heart disease due to a cardiac conduction abnormality requiring a pacemaker, neurologic or psychiatric disorders requiring electroconvulsive therapy, acute or chronic liver diseases, malignancy, severe systemic allergy, etc.) that in the opinion of the Investigator, would expose the subject to an undue risk of a significant adverse event or interfere with the administration of EYS606 or the evaluation of its safety or efficacy during the course of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308045


Contacts
Layout table for location contacts
Contact: Ronald R Buggage, MD 337 6081 3157 Ronald.Buggage@eyevensys.com

Locations
Layout table for location information
France
CHU de Grenoble - Hôpital Michallon Recruiting
Grenoble, France, 38043
Contact: Zineb Baldi       zbaidi@chu-grenoble.fr   
Hôpital Cochin Recruiting
Paris, France, 75014
Contact: Souhila Kecili       souhila.kecili@aphp.fr   
Contact: Cigdem CK KARAYAPICI       cigdem.karayapici@gmail.com   
United Kingdom
Bristol Eye Hospital Active, not recruiting
Bristol, United Kingdom, BS1 2LX
Moorfields Eye Hospital Active, not recruiting
London, United Kingdom
Sponsors and Collaborators
EYEVENSYS S.A.S.
Investigators
Layout table for investigator information
Principal Investigator: Antoine AB BREZIN, MD Hôpital Cochin - Paris - France
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: EYEVENSYS S.A.S.
ClinicalTrials.gov Identifier: NCT03308045    
Other Study ID Numbers: EYS606-CT1
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eyevensys ( EYEVENSYS S.A.S. ):
plasmid
electrotransfer
ciliary muscle
uveitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Uveitis
Panuveitis
Uveal Diseases
Eye Diseases